How to Buy Hester Biosciences Ltd Shares?
You can easily buy the stocks/shares of Hester Biosciences Ltd (HESTERBIO) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Hester Biosciences Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of HESTERBIO as on 15th May 2025 is ₹1806.12What is the return on Hester Biosciences Ltd share?
The past returns of Hester Biosciences Ltd (HESTERBIO) share are- Past 1 week: N/A
- Past 1 month: -59.92
- Past 3 months: 37.46
- Past 6 months: -24.04
- Past 1 year: -1.69
- Past 3 years: -18.00
- Past 5 years: 50.13
What is the Dividend yield % on Hester Biosciences Ltd share?
The current dividend yield of Hester Biosciences Ltd (HESTERBIO) is 0.38What is the Market Cap of Hester Biosciences Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hester Biosciences Ltd (HESTERBIO) is ₹1579.34Cr as of 15th May 2025What is the 52 Week High and Low of Hester Biosciences Ltd?
The 52-week high and low of Hester Biosciences Ltd (HESTERBIO) is ₹3379 and ₹1242.95.What is the PE and PB ratio of Hester Biosciences Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Hester Biosciences Ltd are 57.43 and 5.21 respectively.Which sector does Hester Biosciences Ltd belong to?
Hester Biosciences Ltd (HESTERBIO) belongs to the Health Care sector & Biotechnology sub-sector.What are the peers or stocks similar to Hester Biosciences Ltd?
The peers or stocks similar to Hester Biosciences Ltd are: and many others.Can't decide whether or not to buy Hester Biosciences Ltd?
Worry no more! Login to Tickertape and check out Hester Biosciences Ltd (HESTERBIO) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Hester Biosciences Ltd?
The 52-week high and low of Hester Biosciences Ltd (HESTERBIO) is ₹3379 and ₹1242.95.1. Test Stocks FAQ for Hester Biosciences Ltd Shares?
You can easily buy the stocks/shares of Hester Biosciences Ltd (HESTERBIO) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Hester Biosciences Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of HESTERBIO as on 15th May 2025 is ₹1806.12
Hester Biosciences Ltd
HESTERBIO Share Price
1,806.120.04% (-0.68)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
HESTERBIO Performance & Key Metrics
HESTERBIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 57.47 | 5.21 | 0.38% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
HESTERBIO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
HESTERBIO Company Profile
Hester Biosciences Limited is engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include Poultry Division and Large Animal Division.
BIOCON
PE Ratio
41.96
41.96
1Y Return
5.10%
5.10%
Buy Reco %
63.64
63.64
ONESOURCE
PE Ratio
-1,288.76
-1,288.76
1Y Return
18.44%
18.44%
Buy Reco %
—
—
SAILIFE
PE Ratio
94.24
94.24
1Y Return
11.24%
11.24%
Buy Reco %
—
—
ACUTAAS
PE Ratio
56.91
56.91
1Y Return
66.85%
66.85%
Buy Reco %
100.00
100.00
PANACEABIO
PE Ratio
-329.60
-329.60
1Y Return
237.90%
237.90%
Buy Reco %
—
—
HESTERBIO Sentiment Analysis
HESTERBIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
HESTERBIO Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
HESTERBIO Stock Growth Drivers
HESTERBIO Stock Growth Drivers
4Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
Stable Financial Metrics
The company has maintained a return on assets (ROA) of 1.9% post-merger, showcasing stability in
HESTERBIO Stock Challenges
HESTERBIO Stock Challenges
5Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
HESTERBIO Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
HESTERBIO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
HESTERBIO
HESTERBIO
Income
Balance Sheet
Cash Flow
Annual Normal View
HESTERBIO Income Statement
HESTERBIO Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 123.53 | 138.49 | 185.28 | 189.64 | 219.01 | 249.17 | 285.65 | 319.80 | 319.13 | 319.13 | ||||||||||
Raw Materials | 29.11 | 35.39 | 41.92 | 44.15 | 46.63 | 75.41 | 82.74 | 87.14 | 250.05 | 250.05 | ||||||||||
| Power & Fuel Cost | 5.59 | 6.37 | 7.83 | 8.13 | 7.57 | 10.28 | 12.74 | 15.30 | ||||||||||||
| Employee Cost | 18.32 | 23.24 | 28.93 | 40.65 | 38.92 | 45.33 | 56.02 | 64.13 | ||||||||||||
| Selling & Administrative Expenses | 15.93 | 17.92 | 24.99 | 37.78 | 35.47 | 40.18 | 54.77 | 56.48 | ||||||||||||
| Operating & Other expenses | 13.15 | 5.75 | 6.36 | -2.85 | 20.41 | 3.82 | 9.22 | 27.85 | ||||||||||||
EBITDA | 41.43 | 49.82 | 75.25 | 61.78 | 70.01 | 74.15 | 70.16 | 68.90 | 69.08 | 69.08 | ||||||||||
| Depreciation/Amortization | 7.00 | 9.66 | 11.76 | 13.07 | 13.31 | 16.58 | 20.70 | 17.17 | 16.80 | 16.80 | ||||||||||
| PBIT | 34.43 | 40.16 | 63.49 | 48.71 | 56.70 | 57.57 | 49.46 | 51.73 | 52.28 | 52.28 | ||||||||||
| Interest & Other Items | 3.50 | 4.04 | 6.63 | 7.37 | 6.60 | 4.06 | 9.32 | 19.78 | 12.70 | 12.71 | ||||||||||
| PBT | 30.93 | 36.12 | 56.86 | 41.34 | 50.10 | 53.51 | 40.14 | 31.95 | 39.58 | 39.57 | ||||||||||
| Taxes & Other Items | 7.38 | 10.51 | 15.29 | 12.16 | 15.68 | 14.17 | 13.53 | 13.07 | 12.08 | 12.09 | ||||||||||
| Net Income | 23.55 | 25.61 | 41.57 | 29.18 | 34.42 | 39.34 | 26.61 | 18.88 | 27.50 | 27.48 | ||||||||||
| EPS | 27.68 | 30.11 | 48.87 | 34.30 | 40.46 | 46.25 | 31.28 | 22.19 | 33.89 | 32.30 | ||||||||||
| DPS | 5.30 | 10.00 | 11.00 | 6.60 | 10.00 | 10.00 | 8.00 | 6.00 | 7.00 | 6.00 | ||||||||||
| Payout ratio | 0.19 | 0.33 | 0.23 | 0.19 | 0.25 | 0.22 | 0.26 | 0.27 | 0.21 | 0.19 |
HESTERBIO Company Updates
HESTERBIO Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
HESTERBIO Past Performance & Peer Comparison
HESTERBIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation-basic on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Hester Biosciences Ltd | 57.43 | 5.21 | 0.38% |
| Biocon Ltd | 41.96 | 1.68 | 0.35% |
| Onesource Specialty Pharma Ltd | -1,288.76 | 58.49 | — |
| Sai Life Sciences Ltd | 94.24 | 16.44 | — |
HESTERBIO Stock Price Comparison
Compare HESTERBIO with any stock or ETFCompare HESTERBIO with any stock or ETF
HESTERBIO
HESTERBIO Holdings
HESTERBIO Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
HESTERBIO Promoter Holdings Trend
HESTERBIO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
HESTERBIO Institutional Holdings Trend
HESTERBIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
HESTERBIO Shareholding Pattern
HESTERBIO Shareholding Pattern
HESTERBIO Shareholding History
HESTERBIO Shareholding History
Foreign Institutions
Mutual Funds Invested in HESTERBIO
Mutual Funds Invested in HESTERBIO
No mutual funds holding trends are available
Top 1 Mutual Funds holding Hester Biosciences Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.05% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 89/102 (-3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing HESTERBIO stock
smallcases containing HESTERBIO stock
Looks like this stock is not in any smallcase yet.
HESTERBIO Events
HESTERBIO Events
HESTERBIO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HESTERBIO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.38%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.77 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
HESTERBIO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HESTERBIO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.38%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.77 every year
HESTERBIO Upcoming Dividends
HESTERBIO Upcoming Dividends
No upcoming dividends are available
HESTERBIO Past Dividends
HESTERBIO Past Dividends
Cash Dividend
Ex DateEx DateAug 22, 2024
Final
Final | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Aug 22, 2024
Cash Dividend
Ex DateEx DateSep 12, 2023
Final
Final | Div/Share: ₹8.00
Dividend/Share
₹8.00
Ex DateEx Date
Sep 12, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Final
Final | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Final
Final | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateAug 27, 2020
Final
Final | Div/Share: ₹6.60
Dividend/Share
₹6.60
Ex DateEx Date
Aug 27, 2020
HESTERBIO Stock News & Opinions
HESTERBIO Stock News & Opinions
Articles & Videos
Spotlight
Hester Biosciences registers 30% YoY jump in Q4 PAT PAT to Rs 9.6 crore
The Animal Division, which includes both Ruminants and Pet health products, reported an 8% growth in revenue to Rs 30.53 crore in Q4 FY25. The Poultry Healthcare division's revenue grew by 3% YoY to Rs 46.08 crore during the period under review. While EBITDA expanded by 8% YoY to Rs 14.76 crore, EBITDA margin remained constant at 19%. On a consolidated basis, the company has recorded 76% drop in net profit to Rs 1.54 crore even as a revenues increased by 3% to Rs 81.92 crore in Q4 FY25 over Q4 FY24. For FY25, Hester Bio has registered a net profit of Rs 28.82 crore (up 36% YoY) and revenue from operations of Rs 304.54 crore (up 2% YoY). In its outlook, the company said that it remains focused on deepening its presence across all core segments while maintaining strong operational discipline. The company is on track to launch the Avian Influenza vaccine and expand its portfolio of feed supplements and disinfectants in the Poultry Healthcare Division, creating new domestic and export opportunities. In the Animal Division, efforts will be on broadening the nutritional and therapeutic product range to meet evolving market needs and strengthen market share. Continued investments in product development, supply chain efficiency, and customer engagement will drive sustainable growth. Hester is also prioritising international expansion, with a strong focus on scaling its Africa operations and strengthening its presence in existing and new geographies, aligned with its long-term vision of global leadership in animal healthcare,' the company stated. Hester Biosciences Limited is one of the India's leading animal health company, manufacturing vaccines and health products. It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India. The scrip slipped 3.20% to currently trade at Rs 1643.50 on the BSE. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit declines 73.94% in the March 2025 quarter
Net profit of Hester Biosciences declined 73.94% to Rs 1.29 crore in the quarter ended March 2025 as against Rs 4.95 crore during the previous quarter ended March 2024. Sales rose 3.37% to Rs 81.93 crore in the quarter ended March 2025 as against Rs 79.26 crore during the previous quarter ended March 2024. For the full year,net profit rose 45.53% to Rs 27.49 crore in the year ended March 2025 as against Rs 18.89 crore during the previous year ended March 2024. Sales rose 2.15% to Rs 311.10 crore in the year ended March 2025 as against Rs 304.55 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales81.9379.26 3 311.10304.55 2 OPM %23.4120.09 -19.6317.62 - PBDT7.9213.61 -42 56.3749.13 15 PBT3.759.87 -62 39.5731.95 24 NP1.294.95 -74 27.4918.89 46 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Hester Biosciences recommends final dividend
Hester Biosciences announced that the Board of Directors of the Company at its meeting held on 9 May 2025, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Hester Biosciences to conduct board meeting
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 9 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit rises 192.96% in the December 2024 quarter
Net profit of Hester Biosciences rose 192.96% to Rs 11.66 crore in the quarter ended December 2024 as against Rs 3.98 crore during the previous quarter ended December 2023. Sales declined 5.61% to Rs 63.22 crore in the quarter ended December 2024 as against Rs 66.98 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales63.2266.98 -6 OPM %8.0215.15 - PBDT17.6610.16 74 PBT13.376.41 109 NP11.663.98 193 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Hester Biosciences to declare Quarterly Result
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 30 January 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit rises 100.49% in the September 2024 quarter
Net profit of Hester Biosciences rose 100.49% to Rs 8.20 crore in the quarter ended September 2024 as against Rs 4.09 crore during the previous quarter ended September 2023. Sales rose 18.78% to Rs 83.69 crore in the quarter ended September 2024 as against Rs 70.46 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales83.6970.46 19 OPM %22.8918.75 - PBDT16.0711.05 45 PBT11.876.76 76 NP8.204.09 100 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Hester Biosciences to hold AGM
Hester Biosciences announced that the Annual General Meeting (AGM) of the company will be held on 29 August 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Hester Biosciences schedules board meeting
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Hester Biosciences Ltd leads gainers in ‘B’ group
11 months agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of 11.53%, vs industry avg of 19.23%
Over the last 5 years, market share decreased from 2.34% to 1.67%
Over the last 5 years, net income has grown at a yearly rate of -14.6%, vs industry avg of 2.33%